

# Ioannis Ntanasis-Stathopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5424641/publications.pdf>

Version: 2024-02-01

178  
papers

5,897  
citations

145106  
33  
h-index

107981  
68  
g-index

180  
all docs

180  
docs citations

180  
times ranked

10516  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	1.9	30
2	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	1.2	18
3	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
4	Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. <i>American Journal of Hematology</i> , 2022, 97, 119-128.	2.0	36
5	Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	2.0	12
6	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 335-347.	0.9	4
7	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	2.5	10
8	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	1.4	7
9	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	0.6	28
10	Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	10
11	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery”The Prospective Observational ROADMAP-Post COVID-19 Study. <i>Hemato</i> , 2022, 3, 111-121.	0.2	4
12	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
13	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	1.2	17
14	Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2022, 197, 576-579.	1.2	6
15	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.	3.6	18
16	Diabetes mellitus and multiple myeloma; common features of two distinct entities. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3535.	1.7	4
17	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	1.0	2
18	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study of REBUILD. <i>Cancers</i> , 2022, 14, 2768.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Chromosome 1q21 aberrations identify ultra <sc>high-risk</sc> myeloma with prognostic and clinical implications. American Journal of Hematology, 2022, 97, 1142-1149.	2.0	10
20	Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals. HemaSphere, 2022, 6, e747.	1.2	6
21	Controversies in the use of new bone-modifying therapies in multiple myeloma. British Journal of Haematology, 2021, 193, 1034-1043.	1.2	13
22	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 3-11.	1.4	18
23	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	1.9	232
24	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	1.2	15
25	Screening for Gaucher disease among patients with plasma cell dyscrasias. Leukemia and Lymphoma, 2021, 62, 761-763.	0.6	2
26	COVID-19: time to flatten the infodemic curve. Clinical and Experimental Medicine, 2021, 21, 161-165.	1.9	27
27	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. Therapeutic Advances in Hematology, 2021, 12, 204062072198958.	1.1	11
28	Therapy of Myeloma Bone Disease. , 2021, , 111-137.		0
29	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. HemaSphere, 2021, 5, e547.	1.2	31
30	Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. International Journal of Molecular Sciences, 2021, 22, 2375.	1.8	17
31	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 2021, 13, 1257.	1.7	9
32	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	5.1	92
33	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms, 2021, 9, 546.	1.6	14
34	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. American Journal of Roentgenology, 2021, 216, 742-751.	1.0	8
35	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines, 2021, 9, 422.	2.1	8
36	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	0.6	130

#	ARTICLE	IF	CITATIONS
37	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1509.	1.0	2
38	The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4462.	1.8	39
39	Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19. <i>Diagnostics</i> , 2021, 11, 995.	1.3	16
40	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. <i>American Journal of Hematology</i> , 2021, 96, E321-E324.	2.0	17
41	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 379-385.	0.2	11
42	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	1.7	12
43	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.	1.7	127
44	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	2.1	25
45	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	1.8	38
46	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. <i>European Journal of Internal Medicine</i> , 2021, 89, 87-96.	1.0	53
47	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. <i>Cancers</i> , 2021, 13, 4047.	1.7	8
48	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	2.8	103
49	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	1.7	44
50	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	2.5	39
51	BCMA in Multiple Myeloma "A Promising Key to Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4088.	1.0	25
52	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	1.5	26
53	Metabolic Disorders in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11430.	1.8	16
54	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	1.7	6
56	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	0.6	0
57	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3886-3886.	0.6	5
58	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2736-2736.	0.6	4
59	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793953.	2.2	25
60	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. <i>Biomedicines</i> , 2021, 9, 1811.	1.4	8
61	Clear cell sugar tumor of the lung; a systematic review for a rare entity. <i>Jbuon</i> , 2021, 26, 17-32.	0.3	0
62	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	1.8	13
63	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	3.4	42
64	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.	0.2	10
65	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 93.	2.8	13
66	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	1.0	1
67	&lt;p&gt;Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6405-6416.	1.0	12
68	Cholangiocarcinoma: investigations into pathway-targeted therapies. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 765-773.	1.1	13
69	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.	1.9	351
70	Antiâ€SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020, 8, 1885.	1.6	39
71	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	1.7	24
72	Multiple myeloma: Current and future management in the aging population. <i>Maturitas</i> , 2020, 138, 8-13.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	0.8	9
74	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.	0.6	0
75	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 860.	1.3	35
76	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25.	2.8	16
77	The current role of BTK inhibitors in the treatment of Waldenström's Macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 663-674.	1.1	4
78	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.	1.2	14
79	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e905-e909.	0.2	9
80	Antibody therapies for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 295-303.	1.4	7
81	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.2	23
82	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	2.0	12
83	Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 834-847.	2.0	1,354
84	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	0.8	31
85	Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 499-508.	0.2	11
86	CCL3 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 13-21.	0.8	60
87	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
88	Liver Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 227-241.	0.8	8
89	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond Tj ETQq1 1 0.784314 rgBT /Oyerlock 10	0.1	2
90	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	0.6	0

#	ARTICLE	IF	CITATIONS
91	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.	0.6	0
92	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	0.6	0
93	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.	0.6	1
94	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020, 136, 21-21.	0.6	4
95	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
96	Current trends in the management and prevention of human papillomavirus (HPV) infection. <i>Jbuon</i> , 2020, 25, 1281-1285.	0.3	1
97	Current Approaches in the Management of Hepatic Adenomas. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 199-209.	0.9	21
98	Prevention and treatment of childhood and adolescent obesity: a systematic review of meta-analyses. <i>World Journal of Pediatrics</i> , 2019, 15, 350-381.	0.8	49
99	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?. <i>Expert Review of Hematology</i> , 2019, 12, 651-663.	1.0	12
100	&lt;p&gt;Evaluating ibrutinib in the treatment of symptomatic Waldenstromâ€™s macroglobulinemia&lt;/p&gt;. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.	0.7	13
101	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	1.1	8
102	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S325.	0.2	0
103	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S331-S332.	0.2	0
104	Real World Treatment of Patients with Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S24-S27.	0.2	1
105	Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1044-1054.	0.9	39
106	Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. <i>Hematology</i> , 2019, 24, 318-324.	0.7	6
107	Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. <i>Annals of Hematology</i> , 2019, 98, 1583-1592.	0.8	1
108	Meat, fish, dairy products and risk of hematological malignancies in adults â€“ a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2019, 60, 1978-1990.	0.6	15

#	ARTICLE	IF	CITATIONS
109	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	0.8	9
110	Updates on thrombotic events associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 355-365.	1.0	11
111	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e324-e336.	0.2	13
112	Disappearing liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2019, 29, 7-13.	0.8	30
113	Anti-BCMA antibodies in the future management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 319-326.	1.1	19
114	Myeloma bone disease: from biology findings to treatment approaches. <i>Blood</i> , 2019, 133, 1534-1539.	0.6	88
115	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 2-10.	1.0	10
116	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	1.2	20
117	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	2.5	17
118	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	2.5	37
119	Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy. <i>Medicine (United States)</i> , 2019, 98, 10784-10791.	1.0	14
120	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	0.2	2
121	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	2.0	21
122	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	2.3	10
123	Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies. <i>International Journal of Cancer</i> , 2019, 145, 347-359.	2.3	36
124	Vulnerability variables among octogenarian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	0.6	9
125	Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 3118-3118.	0.6	4
126	Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study). <i>Blood</i> , 2019, 134, 1837-1837.	0.6	2



#	ARTICLE	IF	CITATIONS
127	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 5528-5528.	0.6	1
128	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019, 134, 1877-1877.	0.6	0
129	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2019, 134, 1842-1842.	0.6	0
130	Multidisciplinary management of complicated small bowel adenocarcinoma on the ground of Crohn's disease. <i>Jbuon</i> , 2019, 24, 408-409.	0.3	0
131	Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies. <i>International Journal of Cancer</i> , 2018, 143, 486-495.	2.3	36
132	Clear cell "oesugar tumor" of the lung: Diagnostic features of a rare pulmonary tumor. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 52-54.	0.2	9
133	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. <i>Blood Cancer Journal</i> , 2018, 8, 7.	2.8	219
134	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenstr"m Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	0.2	5
135	Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 927-938.	0.5	97
136	Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2018, 59, 434-447.	0.6	23
137	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	0.6	6
138	Updates and Critical Insights on Glissonian Approach in Liver Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 154-163.	0.9	18
139	Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review. <i>Journal of Surgical Oncology</i> , 2018, 117, 341-353.	0.8	61
140	Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases. <i>Annals of Surgery</i> , 2018, 267, 1047-1055.	2.1	102
141	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	0.6	54
142	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2018, 59, 983-987.	0.6	4
143	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	1.4	24
144	Micronutrient Intake and Risk of Hematological Malignancies in Adults: A Systematic Review and Meta-analysis of Cohort Studies. <i>Nutrition and Cancer</i> , 2018, 70, 821-839.	0.9	12

#	ARTICLE	IF	CITATIONS
145	Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. <i>Blood Advances</i> , 2018, 2, 2837-2847.	2.5	14
146	Cytokines as biomarkers of inflammatory response after open versus endovascular repair of abdominal aortic aneurysms: a systematic review. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1164-1175.	2.8	30
147	Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. <i>Surgical Oncology</i> , 2018, 27, 611-618.	0.8	57
148	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	3.3	40
149	Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2018, 27, 280-288.	0.8	132
150	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	2.8	29
151	How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018, 10, 4248-4268.	1.4	9
152	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	0.8	6
153	Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 601-611.	0.5	64
154	Update on Surgical Management of Small Bowel Neuroendocrine Tumors. <i>Anticancer Research</i> , 2018, 38, 1267-1278.	0.5	23
155	Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 153-163.	1.0	7
156	Endobronchial Carcinoid Tumor Totally Occluding the Left Main Bronchus Without Producing Symptoms of Bronchial Obstruction. <i>In Vivo</i> , 2018, 31, 1023-1025.	0.6	3
157	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. <i>Blood</i> , 2018, 132, 1978-1978.	0.6	1
158	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. <i>Blood</i> , 2018, 132, 1968-1968.	0.6	1
159	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Blood</i> , 2018, 132, 3248-3248.	0.6	0
160	Challenging differential diagnosis of an extra-adrenal paraganglioma; the role of fine needle aspiration cytology. <i>Diagnostic Cytopathology</i> , 2017, 45, 565-568.	0.5	4
161	Adipose-derived stem cells for breast reconstruction after breast surgery – preliminary results. <i>Case Reports in Plastic Surgery &amp; Hand Surgery</i> , 2017, 4, 35-41.	0.1	9
162	Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. <i>Surgery</i> , 2017, 162, 525-536.	1.0	126

#	ARTICLE	IF	CITATIONS
163	Squamous cell carcinoma of the pancreas: A systematic review and pooled survival analysis. <i>European Journal of Cancer</i> , 2017, 79, 193-204.	1.3	29
164	Intraductal papilloma of the breast in an 11-year-old male patient: a case report. <i>Pediatric Surgery International</i> , 2017, 33, 727-730.	0.6	4
165	Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. <i>Surgical Oncology</i> , 2017, 26, 423-430.	0.8	20
166	The association between pulse wave velocity and peripheral neuropathy in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1624-1629.	1.2	19
167	The Role of Endoscopic Ultrasound in the Diagnosis and Management of Primary Gastric Lymphoma. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-6.	0.7	15
168	Combined Use of Mammography and FNA Eliminates Pitfalls in the Management of Metaplastic Breast Carcinoma. <i>In Vivo</i> , 2017, 31, 737-740.	0.6	2
169	The role of BioGlue in thoracic surgery: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 568-576.	0.6	19
170	Successful treatment with lenalidomide dexamethasone for second relapse of a patient with non-secretory multiple myeloma with extramedullary liver plasmacytomas: A case report. <i>Hematology &amp; Medical Oncology</i> , 2017, 2, .	0.1	1
171	Challenging management of synchronous cancers presenting with dysphagia. <i>Journal of B U on</i> , 2017, 22, 280-281.	0.4	0
172	Esophageal remnant cancer 35 years after acidic caustic injury: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 25, 215-217.	0.2	8
173	Association between problematic internet use, socio-demographic variables and obesity among European adolescents. <i>European Journal of Public Health</i> , 2016, 26, 617-622.	0.1	58
174	The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review. <i>Cancer Investigation</i> , 2016, 34, 313-339.	0.6	17
175	Physical Activity and Gastric Cancer Risk. <i>Clinical Journal of Sport Medicine</i> , 2016, 26, 445-464.	0.9	39
176	Management and Outcomes in Metaplastic Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 437-443.	1.1	66
177	Insulin resistance and cardiometabolic risk factors in obese children and adolescents: a hierarchical approach. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2015, 28, 589-96.	0.4	14
178	Obesity and Risk for Brain/CNS Tumors, Gliomas and Meningiomas: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0136974.	1.1	64